

Newsletter



Northern Lincolnshire Area Prescribing Committee

Introduction

The APC met on 28th November to further develop prescribing options and shared care in Northern Lincolnshire. The focus of the November meeting was mental health and in particular ADHD. There has historically been a very complex system of assessment, diagnosis, medicine initiation, medicine continuation and patient reviews. The APC (representing North Lincolnshire CCG, North East Lincolnshire CCG and NLaG) are working with partner organisations, including RDaSH, NAViGO and LPFT to streamline processes, increase efficiency for patients, create effective, standardised communication pathways and unify prescribing outcomes.

The APC is seeking clinicians from both primary and secondary care to support the creation of a Shared Care Guideline for DMARDs. Involvement from any clinician with an interest in this area would be greatly appreciated. Interested parties are requested to contact Richard Neilson on 07780 811 118 in the first instance.

New Patient Treatments

Ceftaroline fosamil 600mg IV injection (brand name Zinforo) has been added to the Formulary. This will primarily be used to treat community acquired pneumonia (CAP) and is for secondary care use only. Ceftaroline has been added to Formulary Chapter 5.1.2.1.

Pentoxifylline 400mg MR Tablets (brand name Trental 400) have been added to the Formulary for use in patients with Behcets disease. For this condition, these tablets will be Consultant Immunologist initiated. Subject to correct communication and agreement, this medicine can be continued by primary care providing a positive clinical outcome is achieved. This has been added to Formulary Chapter 2.6.4.

NICE have supported ocriplasmin intravitreal injection 2.5mg/ml (brand name Jetrea) for adults with vitreomacular traction as per the pathway outlined in TA297. For information only, the SMC have not supported this for use in Scotland. This medicine has been added to the Formulary and can be prescribed subject to an Individual Funding Request (IFR) for each patient. Outcomes resulting from the use of ocriplasmin require strict monitoring. This has been added to Formulary Chapter 11.8.2.

The Prescribing Formulary and related information can be found here: www.northernlincolnshireapc.nhs.uk.